SyneuRx International (Taiwan) Corp.

Equities

6575

TW0006575004

Biotechnology & Medical Research

End-of-day quote Taipei Exchange Other stock markets 23:00:00 05/01/2023 GMT			5-day change	1st Jan Change
17.2 ^TWD	-.--%		-.--%	-.--%

04-29	SyneuRx International Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	SyneuRx International Corp. Reports Earnings Results for the Half Year Ended June 30, 2023	CI

Syneurx International Taiwan Corp. Reports Earnings Results for the Full Year Ended December 31, 2020

March 08, 2021 at 08:09 pm

SyneuRx International Taiwan Corp. announced earnings results for the full year ended December 31, 2020. For the full year, the company announced operating loss was TWD 211.870 million compared to TWD 223.652 million a year ago. Net loss was TWD 219.291 million compared to TWD 223.475 million a year ago. Basic loss per share from continuing operations was TWD 1.99 compared to TWD 2.14 a year ago.

Latest news about SyneuRx International (Taiwan) Corp.

SyneuRx International Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	04-29	CI
SyneuRx International Corp. Reports Earnings Results for the Half Year Ended June 30, 2023	11/08/23	CI
SyneuRx International Corp. Reports Earnings Results for the Full Year Ended December 31, 2022	28/04/23	CI
SyneuRx International Corp.(TPEX:6575) dropped from S&P Global BMI Index	01/02/23	CI
SyneuRx International Corp. Reports Earnings Results for the Half Year Ended June 30, 2022	14/08/22	CI
SyneuRx Announces Final Results of Phase 2 Clinical Trial of COVID-19 Oral Antiviral Candidate Pentarlandir®	31/07/22	CI
SyneuRx™ International Reaches Target Enrollment in Phase 2 Clinical Trial of COVID-19 Oral Antiviral Candidate Pentarlandir®	13/04/22	CI
SyneuRx International Corp. Reports Earnings Results for the Full Year Ended December 31, 2021	08/04/22	CI
SyneuRx Announces Oral COVID-19 Antiviral Drug Candidate Pentarlandir® Is Showing Effectiveness Against Both the Omicron and Delta COVID-19 Variants	06/01/22	CI
SyneuRx Announces Oral COVID-19 Twindemic Antiviral Drug Candidate Pentarlandir Has Entered Final Portion of FDA Phase II Testing	19/11/21	CI
Syneurx International Taiwan Corp. Reports Earnings Results for the Full Year Ended December 31, 2020	08/03/21	CI
Syneurx International Taiwan Corp. Reports Earnings Results for the Half Year Ended June 30, 2020	12/08/20	CI
Syneurx International Taiwan Corp. Reports Earnings Results for the Full Year Ended December 31, 2019	27/04/20	CI
Syneurx International Taiwan Corp. Reports Earnings Results for the Half Year Ended June 30, 2019	13/08/19	CI
Syneurx International Taiwan Corp. Reports Earnings Results for the Full Year Ended December 31, 2018	28/04/19	CI
SyneuRx International Corp.(GTSM:6575) added to S&P Global BMI Index	21/03/16	CI

Chart SyneuRx International (Taiwan) Corp.

Duration

Period

Chart SyneuRx International (Taiwan) Corp.

More charts

Company Profile

SyneuRx International Taiwan Corp is a Taiwan-based company mainly engaged in the development of new drugs. The Company is mainly engaged in the research and development of new drugs for treatment of coronavirus disease (COVID-19), schizophrenia, dementia and depression. Its clinical trials include SNB01 COVID-19 Antiviral, SND13 Adult Schizophrenia Study, SND12 Refractory Schizophrenia and SND11 Adolescent Schizophrenia.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
SYNEURX INTERNATIONAL (TAIWAN) CORP.	-.--%	71.83M
VERTEX PHARMACEUTICALS INCORPORATED	+15.19%	121B
REGENERON PHARMACEUTICALS, INC.	+19.91%	114B
ARGENX SE	+18.81%	23.61B
BIONTECH SE	-19.80%	20.43B
GENMAB A/S	-15.64%	16.55B
BEIGENE, LTD.	-13.45%	16.45B
WUXI APPTEC CO., LTD.	-44.35%	15.59B
SAREPTA THERAPEUTICS, INC.	+66.67%	15.19B
NEUROCRINE BIOSCIENCES, INC.	+2.13%	13.54B

Bio Therapeutic Drugs